Who Paid My Doc
Matt Havens
Physician Assistant, Medical Bolivar, MO Physician Assistant
NPI 1992912216 CMS profile 10794062
1300 N Oakland Ave, Suite A, Bolivar, MO 65613
General payments
$3,266
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Matt Havens of Bolivar, MO is reported in the CMS Open Payments database as having received $3,266 across 188 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 83rd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $901 | 50 | |
| 2024 | General | $969 | 55 | |
| 2023 | General | $598 | 33 | |
| 2022 | General | $431 | 26 | |
| 2021 | General | $366 | 24 |
Beside peers
- Matt Havens
- Physician Assistant, Medical median
- Middle half of Physician Assistant, Medical
- National median
In program year 2025, general payments to Matt Havens were reported at $901. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.
Show as a table
| Year | Matt Havens | Physician Assistant, Medical median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $61 | $19–$193 | $163 |
| 2020 | $0 | $20 | $14–$64 | $114 |
| 2021 | $366 | $156 | $41–$563 | $132 |
| 2022 | $431 | $185 | $55–$649 | $149 |
| 2023 | $598 | $199 | $58–$717 | $160 |
| 2024 | $969 | $206 | $62–$740 | $164 |
| 2025 | $901 | $214 | $62–$755 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 135 drugsPart D claims
8,546
Drug cost
$618,897
Branded share of claims
19.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 86 | $91,877 | |
| Eliquis Apixaban | Brand | 57 | $52,678 | |
| Mounjaro Tirzepatide | Brand | 46 | $51,518 | |
| Jardiance Empagliflozin | Brand | 43 | $50,579 | |
| Trulicity Dulaglutide | Brand | 37 | $41,162 | |
| Xarelto Rivaroxaban | Brand | 27 | $38,348 | |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | Brand | 72 | $38,219 | |
| Nurtec Odt Rimegepant Sulfate | Brand | 22 | $36,383 | |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | Brand | 44 | $29,565 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 33 | $25,190 |
The 10 drugs with the highest cost, of 135 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 19 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| VRAYLAR |
|
$272 | — | — |
| NURTEC ODT |
|
$63 | 22 | — |
| ZAVZPRET |
|
$63 | — | — |
| AIRSUPRA |
|
$46 | — | — |
| RYBELSUS |
|
$43 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 19 in the dashboard with a free accountRecords
188 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Physician Assistant, Medical in Missouri
Melanie Chisam
Physician Assistant, Medical · Springfield, MO
Emily Jensen
Physician Assistant, Medical · Bowling Green, MO
Sarah Wilmsmeyer
Physician Assistant, Medical · Chesterfield, MO
Amy Mosman
Physician Assistant, Medical · Saint Louis, MO
Dustin Bartlett
Physician Assistant, Medical · Springfield, MO
Alexa Fider-Whyte
Physician Assistant, Medical · Saint Louis, MO
Related records
Physician Assistant, Medical in Missouri
Practitioners in the same specialty and state, ranked by reported value.
All Physician Assistant, Medical
Everyone recorded under this specialty, nationwide.
Doctors in Missouri
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.